NCT07088380View on ClinicalTrials.gov

Ketamine Augmentation of ECT in Treatment-Resistant Depression

PHASE3RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 10, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Major Depressive DisorderTreatment Resistant Depression
Interventions
DRUG

Ketamine Hydrochloride

Ketamine will be administered intravenously at a subanesthetic dose of 0.5 mg/kg after a bolus of Propofol, during ECT sessions 2, 4, and 6.

DRUG

Placebo

Placebo will be administered intravenously at a subanesthetic dose of 0.5 mg/kg after a bolus of Propofol, during ECT sessions 2, 4, and 6.

Trial Locations (1)

20127

RECRUITING

IRCCS Ospedale San Raffaele Turro, Milan

All Listed Sponsors
lead

Università Vita-Salute San Raffaele

OTHER